Estradiol-induced regression in T47D:A18/PKCα tumors requires the estrogen receptor and interaction with the extracellular matrix

Molecular Cancer Research

Volumn 7, Issue 4, 2009, Pages 498-510

  Zhang, Yiyun ^a   Zhao, Huiping ^a   Asztalos, Szilard ^a   Chisamore, Michael ^b   Sitabkhan, Yasmin ^b   Tonetti, Debra A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN D; ESTRADIOL; ESTROGEN RECEPTOR; FAS ANTIGEN; FAS LIGAND; FULVESTRANT; MATRIGEL; PEPTIDES AND PROTEINS; PROTEIN C3; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; PROTEIN PR; PROTEIN PS2; SHORT HAIRPIN RNA; TAMOXIFEN; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; C3 PROTEIN, HUMAN; COMPLEMENT COMPONENT C3; ESTROGEN; PRESENILIN 2; PROGESTERONE RECEPTOR; PSEN2 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; EXTRACELLULAR MATRIX; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MICROENVIRONMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; TISSUE CULTURE; TUMOR MODEL; TUMOR REGRESSION; WESTERN BLOTTING; ANIMAL; CLONOGENIC ASSAY; DRUG ANTAGONISM; EXPERIMENTAL NEOPLASM; GENETICS; METABOLISM; MOUSE; NUDE MOUSE; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CATHEPSIN D; CELL LINE, TUMOR; COLONY-FORMING UNITS ASSAY; COMPLEMENT C3; ESTRADIOL; ESTROGENS; EXTRACELLULAR MATRIX; FAS LIGAND PROTEIN; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; PRESENILIN-2; PROTEIN KINASE C-ALPHA; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 65549136708     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0415     Document Type: Article

References (81)

1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-88.
2. Jordan VC. Designer estrogens. Sci Am 1998;279:60-67
3. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004;11:643-658 (Pubitemid 40065543)
4. Encarnacion CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SA, Osborne CK. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 1993;26:237-246 (Pubitemid 23304239)
5. Karnik PS, Kulkarni S, Liu XP, Budd GT, Bukowski RM. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res 1994;54:349-353 (Pubitemid 24053165)
6. Robertson JF. Oestrogen receptor: a stable phenotype in breast cancer. Br J Cancer 1996;73:5-12. (Pubitemid 26026252)
7. Osborne CK, Schiff R. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast 2003;12: 362-367 (Pubitemid 38008644)
8. Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R, Grohe C. Estrogen receptor α rapidly activates the IGF-1 receptor pathway. J Biol Chem 2000;275: 18447-18453 (Pubitemid 30414803)
9. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004;10: 331-6S. (Pubitemid 38116639)
10. Borg A, Baldetorp B, Ferno M, et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 1994; 81:137-144
11. Dowsett M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer 2001;8:191-195 (Pubitemid 32947641)
12. Arpino G, Green SJ, Allred DC, et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. Clin Cancer Res 2004;10:5670-5676
13. Tangkeangsirisin W, Hayashi J, Serrero G. PC cell-derived growth factor mediates tamoxifen resistance and promotes tumor growth of human breast cancer cells. Cancer Res 2004;64:1737-1743 (Pubitemid 38428696)
14. Jordan NJ, Gee JM, Barrow D, Wakeling AE, Nicholson RI. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Res Treat 2004;87:167-180 (Pubitemid 39237793)
15. Shoman N, Klassen S, McFadden A, Bickis MG, Torlakovic E, Chibbar R. Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod Pathol 2005;18:250-259 (Pubitemid 40188633)
16. Coutts AS, Murphy LC. Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Res 1998;58:4071-4074 (Pubitemid 28440557)
17. Gee JM, Robertson JF, Ellis IO, Nicholson RI. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 2001;95:247-254 (Pubitemid 32592092)
18. Schiff R, Reddy P, Ahotupa M, et al. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst 2000;92:1926-1934.
19. 2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res 1999;5:251-256
20. Dumont JA, Bitonti AJ, Wallace CD, Baumann RJ, Cashman EA, Cross- Doersen DE. Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Differ 1996;7:351-359 (Pubitemid 26360774)
21. Louie MC, Zou JX, Rabinovich A, Chen HW. ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol Cell Biol 2004;24:5157-5171 (Pubitemid 38738153)
22. Girault I, Lerebours F, Amarir S, et al. Expression analysis of estrogen receptor α coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res 2003;9:1259-1266
23. Ingle JN, Ahmann DL, Green SJ, et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981;304:16-21.
24. Kennedy BJ. Massive estrogen administration in premenopausal women with advanced breast cancer. Cancer Chemother Rep 1962;16:283-284
25. Peethambaram PP, Ingle JN, Suman VJ, Hartmann LC, Loprinzi CL. Randomized trial of diethylstilbestrol vs.tamoxifen in postmenopausal women with metastatic breast cancer.An updated analysis. Breast Cancer Res Treat 1999;54: 117-122 (Pubitemid 29295314)
26. Lonning PE, Taylor PD, Anker G, et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 2001;67:111-116
27. Yao K, Lee ES, Bentrem DJ, et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 2000;6:2028-2036
28. Song RX, Mor G, Naftolin F, et al. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17β-estradiol. J Natl Cancer Inst 2001;93:1714-1723
29. Santen RJ, Song RX, Zhang Z, Yue W, Kumar R. Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer. Apoptotic action of estrogen. Clin Cancer Res 2004;10:337-45S.
30. Lewis JS, Osipo C, Meeke K, et al. Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Mol Biol 2005;94:131-141
31. Chisamore MJ, Ahmed Y, Bentrem DJ, Jordan VC, Tonetti DA. Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Cα. Clin Cancer Res 2001;7:3156-3165 (Pubitemid 32963839)
32. Shim WS, Conaway M, Masamura S, et al. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 2000;141:396-405.
33. Osipo C, Gajdos C, Liu H, Chen B, Jordan VC. Fulvestrant reverses estradiol- induced regression of tamoxifen-stimulated breast cancer by regulating Fas, HER2/neu, and NF-κB. J Natl Cancer Inst 2003;95:1597-1608 (Pubitemid 37455927)
34. Liu H, Lee ES, Gajdos C, et al. Apoptotic action of 17β-estradiol in raloxifene- resistant MCF-7 cells in vitro and in vivo.J Natl Cancer Inst 2003;95: 1586-1597
35. Curtin JF, Cotter TG. Live and let die: regulatory mechanisms in Fasmediated apoptosis.Cell Signal 2003;15:983-992
36. Toillon RA, Descamps S, Adriaenssens E, et al. Normal breast epithelial cells induce apoptosis of breast cancer cells via Fas signaling. Exp Cell Res 2002;275: 31-43.
37. Tonetti DA, Chisamore MJ, Grdina W, Schurz H, Jordan VC. Stable transfection of protein kinase Cα cDNA in hormone-dependent breast cancer cell lines. Br J Cancer 2000;83:782-791
38. Tonetti DA, Morrow M, Kidwai N, Gupta A, Badve S. Elevated protein kinase Cα expression may be predictive of tamoxifen treatment failure. Br J Cancer 2003;88:1400-1402 (Pubitemid 36606422)
39. Dempsey EC, Newton AC, Mochly-Rosen D, et al. Protein kinase C isozymes and the regulation of diverse cell responses. Am J Physiol Lung Cell Mol Physiol 2000;279:L429-38.
40. Mackay HJ, Twelves CJ. Protein kinase C: a target for anticancer drugs? Endocr Relat Cancer 2003;10:389-396
41. Nabha SM, Glaros S, Hong M, et al. Upregulation of PKC-δ contributes to antiestrogen resistance in mammary tumor cells. Oncogene 2005;24:3166-3176
42. 2+-dependent protein kinase of human mammary carcinoma cells: inverse relationship to estrogen receptors. Int J Cancer 1987;40: 344-348
43. Fournier DB, Chisamore M, Lurain JR, Rademaker AW, Jordan VC, Tonetti DA. Protein kinase Cα expression is inversely related to ER status in endometrial carcinoma: possible role in AP-1-mediated proliferation of ER-negative endometrial cancer. Gynecol Oncol 2001;81:366-372 (Pubitemid 32494649)
44. Ways DK, Kukoly CA, deVente J, et al. MCF-7 breast cancer cells transfected with protein kinase C-α exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J Clin Invest 1995;95:1906-1915.
45. Manni A, Buckwalter E, Etindi R, et al. Induction of a less aggressive breast cancer phenotype by protein kinase C-A and -B overexpression. Cell Growth Differ 1996;7:1187-1198
46. Assender JW, Gee JM, Lewis I, Ellis IO, Robertson JF, Nicholson RI. Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer. J Clin Pathol 2007;60:1216-1221 (Pubitemid 350084541)
47. Frankel LB, Lykkesfeldt AE, Hansen JB, Stenvang J. Protein kinase Cα is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells. Breast Cancer Res Treat 2007;104:165-179 (Pubitemid 47084221)
48. Jordan VC, Osipo C, Schafer JM, Fox JE, Cheng D, Liu H. Changing role of the oestrogen receptor in the life and death of breast cancer cells. Breast 2003;12: 432-441 (Pubitemid 38008656)
49. Wijayaratne AL, McDonnell DP. The human estrogen receptor-α is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem 2001;276:35684-35692 (Pubitemid 37384371)
50. Seo HS, Larsimont D, Querton G, et al. Estrogenic and anti-estrogenic regulation of estrogen receptor in MCF-7 breast-cancer cells: comparison of immunocytochemical data with biochemical measurements. Int J Cancer 1998;78: 760-765
51. Van Den Bemd GJ, Kuiper GG, Pols HA, Van Leeuwen JP. Distinct effects on the conformation of estrogen receptor α and β by both the antiestrogens ICI 164,384 and ICI 182,780 leading to opposite effects on receptor stability. Biochem Biophys Res Commun 1999;261:1-5. (Pubitemid 29371608)
52. Reid G, Hubner MR, Metivier R, et al. Cyclic, proteasome-mediated turnover of unliganded and liganded ERα on responsive promoters is an integral feature of estrogen signaling. Mol Cell 2003;11:695-707.
53. Nardulli AM, Katzenellenbogen BS, Monsma FJ, Jr., Miller MA, Ziegler YS, Katzenellenbogen JA. Dynamics of estrogen receptor turnover in uterine cells in vitro and in uteri in vivo. Characterization of the estrogen receptor and its dynamics in MCF-7 human breast cancer cells using a covalently attaching antiestrogen. Endocrinology 1986;119:2038-2046
54. Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993;106:1377-1388 (Pubitemid 24018422)
55. Ingle JN. Estrogen as therapy for breast cancer. Breast Cancer Res 2002;4: 133-136
56. Osipo C, Gajdos C, Cheng D, et al. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. J Steroid Biochem Mol Biol 2005;93: 249-256
57. Song RX, Santen RJ. Apoptotic action of estrogen. Apoptosis 2003;8:55-60. (Pubitemid 36133138)
58. Ingle JN. Sequencing of endocrine therapy in postmenopausal women with advanced breast cancer. Clin Cancer Res 2004;10:362-7S.
59. Lin X, Yu Y, Zhao H, Zhang Y, Manela J, Tonetti DA. Overexpression of PKCα is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model. Carcinogenesis 2006;27:1538-1546 (Pubitemid 44288042)
60. Faridi J, Wang L, Endemann G, Roth RA. Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. Clin Cancer Res 2003;9:2933-2939 (Pubitemid 36993252)
61. Weigelt B, Bissell MJ. Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. Semin Cancer Biol 2008;18: 311-321
62. Ivaska J, Kermorgant S, Whelan R, Parsons M, Ng T, Parker PJ. Integrinprotein kinase C relationships. Biochem Soc Trans 2003;31:90-93
63. 5 [in process citation].Int J Oncol 1999;15:127-136
64. 1 suppresses apoptosis triggered by serum starvation but not phorbol ester in MCF-7 breast cancer cells that overexpress protein kinase C-α. Int J Oncol 2001;18:195-201.
65. Parsons M, Keppler MD, Kline A, et al. Site-directed perturbation of protein kinase C-integrin interaction blocks carcinoma cell chemotaxis. Mol Cell Biol 2002;22:5897-5911
66. Keum E, Kim Y, Kim J, et al. Syndecan-4 regulates localization, activity and stability of protein kinase C-α. Biochem J 2004;378:1007-1014
67. Lim ST, Longley RL, Couchman JR, Woods A. Direct binding of syndecan-4 cytoplasmic domain to the catalytic domain of protein kinase Cα (PKCα) increases focal adhesion localization of PKCα. J Biol Chem 2003;278:13795-13802 (Pubitemid 36799917)
68. Morris C, Wakeling A. Fulvestrant ('Faslodex') - a new treatment option for patients progressing on prior endocrine therapy. Endocr Relat Cancer 2002;9: 267-276 (Pubitemid 36240766)
69. Long X, Nephew KP. Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-α. J Biol Chem 2006;281:9607-9615 (Pubitemid 43864679)
70. Levin ER. Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol 2005;19:1951-1959.
71. Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005;146:624-632 (Pubitemid 40129818)
72. Migliaccio A, Castoria G, Di Domenico M, et al. Steroid-induced androgen receptor-oestradiol receptor β-Src complex triggers prostate cancer cell proliferation. EMBO J 2000;19:5406-5417
73. Levin ER, Pietras RJ. Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat 2008;108:351-361
74. Alzamora R, Harvey BJ. Direct binding and activation of protein kinase C isoforms by steroid hormones. Steroids 2008;73:885-888
75. Y ang JZ, O'Flatharta C, Harvey BJ, Thomas W. Membrane ERα-dependent activation of PKCα in endometrial cancer cells by estradiol. Steroids 2008;73: 1110-1122
76. Saville B, Wormke M, Wang F, et al. Ligand-, cell-, and estrogen receptor subtype (α/β)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem 2000;275:5379-5387
77. Kushner PJ, Agard DA, Greene GL, et al. Estrogen receptor pathways to AP- 1. J Steroid Biochem Mol Biol 2000;74:311-317
78. Roychowdhury D, Lahn M. Antisense therapy directed to protein kinase C-α (Affinitak, LY900003/ISIS 3521): potential role in breast cancer. Semin Oncol 2003;30:30-33 (Pubitemid 36506289)
79. Pink JJ, Bilimoria MM, Assikis J, Jordan VC. Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation [published erratum appears in Br J Cancer 1997;75:1557]. Br J Cancer 1996; 74:1227-1236
80. O'Regan RM, Cisneros A, England GM, et al. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst 1998;90:1552-1558
81. Catherino WH, Jordan VC. Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue. Cancer Lett 1995;92:39-47.